In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Solvay buys Unimed for $108.7mm in cash

Executive Summary

Solvay Pharmaceuticals (women's health, gastroenterology, cardiology, and mental health) is buying Unimed (endocrinology, urology, and infectious diseases) for about $108.7mm, paying $12 in cash for each Unimed common share, about a (pr)10% premium to its 10-day pre-announcement trading price.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies